4C Medical Technologies, a medical device company, has closed a $175 million Series D financing round, led by Boston Scientific Corporation, with additional participation from new and existing shareholders. The funds will support the ongoing global pivotal ATLAS trial and the commercialization of the AltaValve System, the company’s transcatheter mitral valve replacement (TMVR) technology. The ATLAS trial, active in both the U.S. and Europe since October 2024, is evaluating the safety and effectiveness of the AltaValve System in patients with moderate-to-severe or severe mitral regurgitation (MR) who are not eligible for surgery or other transcatheter interventions. The trial includes two cohorts: one targeting patients with moderate or severe mitral annular calcification (MAC) and another for patients with no or mild MAC.
The AltaValve System is designed to address key limitations of traditional TMVR devices by using atrial fixation, which aims to improve treatment applicability and reduce complications linked to anchoring in the left ventricle. The system targets MR, a common and progressive heart valve disease affecting nearly 10 percent of Americans over 75 years old. The financing will accelerate clinical development and commercialization efforts. Jeff Chambers, M.D., Chairman of the Board at 4C Medical, said, "With a strong management team and the trial leadership, this financing strategically positions us to accelerate our progress towards device commercialization."
